{
  "run_id": "4ca2545b-b956-4217-ad0c-77053053e185",
  "prompt_variant_id": "27516782-98c7-447d-9982-e68fca9aaac2",
  "api_config_name": "model_gpt_3_5_turbo",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T16:32:05.882078",
  "end_time": "2025-09-01T16:32:07.685549",
  "duration_ms": 1712.7201557159424,
  "success": true,
  "error_message": "",
  "entities_extracted": 16,
  "entities_mapped": 12,
  "extraction_completeness": 1.0,
  "mapping_accuracy": 0.3,
  "precision": 0.8235294117647058,
  "recall": 0.875,
  "f1_score": 0.8484848484848485,
  "compliance_score": 1.0,
  "token_usage": 3907,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "Conditions",
        "position": 11,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "Conditions",
        "position": 39,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 33,
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 64,
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {},
      "confidence": 0.7,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 89,
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 111,
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {},
      "confidence": 0.9,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 13,
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 39,
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 61,
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "novel HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": "novel",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 19,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.8,
      "source_context": {
        "section": "briefSummary",
        "position": 53,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed on prior trastuzumab-based therapy",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "past"
      },
      "confidence": 0.7,
      "source_context": {
        "section": "briefSummary",
        "position": 99,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefTitle",
        "position": 23,
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III Study",
      "type": "procedure",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "officialTitle",
        "position": 2,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Targeted Therapy",
      "type": "medication",
      "attributes": {},
      "confidence": 0.85,
      "source_context": {
        "section": "officialTitle",
        "position": 12,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "officialTitle",
        "position": 39,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Mapped to CancerCondition as primary cancer diagnosis",
      "id": "50ea9826-6226-4a8d-9349-5cc6e2bf32d5",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Mapped to CancerCondition as cancer type",
      "id": "96c311f2-4b3f-4928-af0f-f04f57eee980",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "Mapped to CancerCondition as specific cancer type",
      "id": "94b9d4ea-a222-4387-b44f-eb70c0ac2745",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Adequate organ function",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "Mapped to CancerCondition as condition related to organ function",
      "id": "be3714f3-f437-4078-96a5-dbff9160e152",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Active brain metastases",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 7",
      "mapping_rationale": "Mapped to CancerCondition as condition related to brain metastases",
      "id": "0eef85e5-d2ce-4b67-b260-10ed3de1748d",
      "llm_source_text_fragment": "Entity index 7",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Pregnancy or breastfeeding",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "Mapped to CancerCondition as condition related to pregnancy or breastfeeding",
      "id": "de93f2bd-2c7c-4d7f-8c82-f744b4fca6c9",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Mapped to CancerCondition as specific cancer type",
      "id": "63f66ba0-39d8-491b-ab0d-4ce8199cffa3",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "progressed on prior trastuzumab-based therapy",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "Mapped to CancerCondition as disease status",
      "id": "fa26e058-7d26-4d32-ad63-3b7e25938996",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "Mapped to CancerCondition as primary cancer diagnosis",
      "id": "34713a81-abdc-47e3-bab5-1bb8b3b242c6",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Metastatic Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "Mapped to CancerCondition as specific cancer type",
      "id": "902915e7-e7b4-403b-80cd-98495616d9f6",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "Phase III Study",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 16",
      "mapping_rationale": "Mapped to CancerRelatedProcedure as a study procedure",
      "id": "c1633ca4-a672-4e02-9ee1-1ce7ee4b2ede",
      "llm_source_text_fragment": "Entity index 16",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Novel Targeted Therapy",
      "mapping_confidence": 0.85,
      "source_text_fragment": "Entity index 17",
      "mapping_rationale": "Mapped to CancerRelatedMedication as a novel targeted therapy",
      "id": "18af65f6-1b06-4b21-869d-84da13847392",
      "llm_source_text_fragment": "Entity index 17",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}